-
China’s National Joint Procurement Office Sets March 2024 for Insulin Contracts Renewal
•
The National Joint Procurement Office in China has released a notification outlining the information and filing requirements for the continuation of insulin drug procurement contracts under the volume-based procurement (VBP) program. The renewal process for these insulin VBP contracts is set to commence from March 15, 2024. The inaugural national-level…
-
WuXi AppTec Posts Modest Revenue Growth Despite Regulatory Hurdles
•
WuXi AppTec (HKG: 2359), a China-based Contract Research Organization (CRO), has released its financial results for 2023, reporting an annual operating revenue of RMB 40.34 billion (USD 5.6 billion), representing a year-on-year (YOY) increase of 2.5%. When excluding COVID-19-related commercial projects, sales experienced a substantial growth of 25.6%. The net…
-
Teruisi Pharma’s TRS005 Receives Support for Breakthrough Designation in China for CD20-Positive Lymphoma
•
The Center for Drug Evaluation (CDE) in China has signaled that Teruisi Pharma’s antibody drug conjugate (ADC), TRS005, which targets CD20, is on track to receive breakthrough therapy designation (BTD) for the treatment of recurrent or refractory CD20-positive diffuse large B-cell lymphoma (DLBCL). The drug is being developed specifically for…
-
Pfizer’s Elrexfio Anticipated for Priority Review in China for Relapsed/Refractory Multiple Myeloma
•
The Center for Drug Evaluation (CDE) in China has indicated that Pfizer (NYSE: PFE)’s Elrexfio (elranatamab), a bispecific antibody targeting BCMA and CD3, is on track for priority review as a potential treatment for triple-class exposed (TCE) relapsed or refractory multiple myeloma (r/r MM). This development signifies a significant step…
-
CDE Seeks Public Feedback on Latest Batch of Generic Drug Reference Preparations
•
The Center for Drug Evaluation (CDE), a key regulatory body overseeing pharmaceutical evaluations in China, has issued a call for feedback on the 80th batch of chemical generic reference preparations. The public consultation period is set to conclude on March 29, 2024. This initiative is part of the CDE’s ongoing…
-
AstraZeneca Caps Monthly Costs for US Patients with Asthma and COPD Inhalers
•
AstraZeneca (AZ; NASDAQ: AZN), a leading UK-based pharmaceutical company, has announced an expansion of its accessibility program for inhaled respiratory drugs in the US. The initiative will cap monthly expenses at USD 35 for eligible patients suffering from asthma and chronic obstructive pulmonary disease (COPD). The savings program includes coverage…
-
Jiangsu Yahong Meditech to Present Phase III Results for Cervical Cancer Treatment at SGO Annual Meeting
•
Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176), a specialist in urogenital cancer treatments, is preparing to unveil key findings from a global multicenter Phase III clinical study on its Cevira (APL-1702) at the Society of Gynecologic Oncology (SGO) annual meeting. The study focuses on the treatment of high-grade squamous…
-
Sino Medical Sciences Secures South Korean Approvals for Three Cardiovascular Devices
•
Sino Medical Sciences Technology Inc., (SHA: 688108), a leading Chinese medical device company, has announced that it has received marketing approvals from South Korean regulatory authorities for three of its cardiovascular products: the HT Supreme drug-eluting stent, the NC ROCKSTAR non-compliant balloon dilation catheter, and the SC HONKYTONK coronary balloon…
